BRCA1 and breast carcinoma: Our primary hypothesis was that among women who underwent genetic testing and received first-course chemotherapy for breast cancer, BRCA1/2 and other PV carriers were more likely than noncarriers to be treated with more intensive chemotherapy regimens, as defined by inclusion of more drugs, anthracyclines, and/or platinums.